Biolife Solutions
BLFSUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- — Prior regular-session close from the quote source.
- — Regular-session low and high so far today.
- — Regular-session shares traded.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- — 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own BLFS if its preservation and cold-chain tools prove embedded enough to turn lumpy revenue recovery into durable operating leverage.
BLFS price history
Loading BLFS and S&P 500 price history…
Loading recent earnings…
Investment thesis
What must happen next
Cell-and-gene-therapy manufacturers keep qualifying BioLife products into regulated workflows, so clinical progress and commercial launches pull through demand rather than customers frequently redesigning around cheaper substitutes.StrengtheningMateriality: High
GAAP annual revenue increased from $68.016 million in FY2023 to $74.647 million in FY2024 and $96.214 million in FY2025. If BioLife remains embedded in workflows, revenue can compound with the therapy market; if not, the business becomes a discretionary tools vendor with weaker durability.
Watch: Thermo Fisher, Cytiva, Azenta, or other life-science suppliers win validation in major cell-and-gene-therapy manufacturing processes as preferred alternatives to BioLife products.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $68.016 million in FY2023 to $74.647 million in FY2024 and $96.214 million in FY2025.
Open source ↗Regulatory and process-validation switching costs protect BioLife’s pricing power because changing preservation or cold-chain components can create requalification risk in high-value patient-material workflows.StrengtheningMateriality: High
GAAP annual gross profit was $62.118 million on $96.214 million of FY2025 revenue, an implied GAAP gross margin of about 64.6%. Gross margin is the clearest evidence that BioLife has specialized value rather than commodity supplier economics.
Watch: Competitors demonstrate equivalent preservation outcomes with simpler bridging data, lowering the perceived risk of switching.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit was $62.118 million on $96.214 million of FY2025 revenue, an implied GAAP gross margin of about.
Open source ↗The focused cell-and-gene-therapy portfolio must scale selling, R&D, and corporate costs below gross profit growth; the economic engine is not yet proven because higher revenue has not consistently produced GAAP operating profit.HoldingMateriality: Medium
GAAP annual operating income improved from a loss of $17.205 million in FY2023 to a loss of $4.477 million in FY2024. Without operating leverage, high gross margins do not translate into owner earnings, and the valuation case depends on hope rather than demonstrated economics.
Watch: FY2025 GAAP annual operating income fell to a loss of $16.602 million despite higher revenue, suggesting operating costs absorbed the gross profit gains.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income improved from a loss of $17.205 million in FY2023 to a loss of $4.477 million in.
Open source ↗BioLife has enough balance-sheet runway to wait for lumpy cell-and-gene-therapy demand to convert, but only if positive operating cash flow persists and cash is not consumed by acquisitions, restructuring, or working-capital swings.HoldingMateriality: Medium
Cash was $33.038 million at FY2025 year-end versus liabilities of $33.996 million. A small supplier with volatile end-market demand can destroy per-share value if it must issue equity before the operating model proves out.
Watch: A renewed biotech funding downturn delays orders from clinical-stage cell-and-gene-therapy customers and stretches receivables.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $33.038 million at FY2025 year-end versus liabilities of $33.996 million.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Cell-and-gene-therapy manufacturers keep qualifying BioLife products into regulated workflows, so clinical progress and commercial launches pull through demand rather than customers frequently redesigning around cheaper substitutes. If BioLife remains embedded in workflows, revenue can compound with the therapy market; if not, the business becomes a discretionary tools vendor with weaker durability.
Regulatory and process-validation switching costs protect BioLife’s pricing power because changing preservation or cold-chain components can create requalification risk in high-value patient-material workflows. Gross margin is the clearest evidence that BioLife has specialized value rather than commodity supplier economics.
The focused cell-and-gene-therapy portfolio must scale selling, R&D, and corporate costs below gross profit growth; the economic engine is not yet proven because higher revenue has not consistently produced GAAP operating profit. Without operating leverage, high gross margins do not translate into owner earnings, and the valuation case depends on hope rather than demonstrated economics.
BioLife has enough balance-sheet runway to wait for lumpy cell-and-gene-therapy demand to convert, but only if positive operating cash flow persists and cash is not consumed by acquisitions, restructuring, or working-capital swings. A small supplier with volatile end-market demand can destroy per-share value if it must issue equity before the operating model proves out.
All standing thesis claims
Original report summary
its preservation and cold-chain tools prove embedded enough to turn lumpy revenue recovery into durable operating leverage.
Bull case and bear case
Bull case and bear case for Biolife Solutions
Where the evidence on Biolife Solutions stands: Holding on the latest evidence (Oct 12, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.
Bull case: what the evidence supports
Cell-and-gene-therapy manufacturers keep qualifying BioLife products into regulated workflows, so clinical progress and commercial launches pull through demand rather than customers frequently redesigning around cheaper substitutes.
Regulatory and process-validation switching costs protect BioLife’s pricing power because changing preservation or cold-chain components can create requalification risk in high-value patient-material workflows.
The focused cell-and-gene-therapy portfolio must scale selling, R&D, and corporate costs below gross profit growth; the economic engine is not yet proven because higher revenue has not consistently produced GAAP operating profit.
BioLife has enough balance-sheet runway to wait for lumpy cell-and-gene-therapy demand to convert, but only if positive operating cash flow persists and cash is not consumed by acquisitions, restructuring, or working-capital swings.
Bear case: what would count against it
Thermo Fisher, Cytiva, Azenta, or other life-science suppliers win validation in major cell-and-gene-therapy manufacturing processes as preferred alternatives to BioLife products.
Competitors demonstrate equivalent preservation outcomes with simpler bridging data, lowering the perceived risk of switching.
FY2025 GAAP annual operating income fell to a loss of $16.602 million despite higher revenue, suggesting operating costs absorbed the gross profit gains.
Thesis-Break Engine
Thesis-break watch · Biolife Solutions
Loading the break-condition record for Biolife Solutions.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedCompleted an acquisition or disposition of assets.
Biolife Solutions filed an SEC 8-K on 2026-10-06: Completed an acquisition or disposition of assets. It is a dated development that tests the current thesis.
- MixedOther material event.
Biolife Solutions filed an SEC 8-K on 2026-09-09: Other material event. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Biolife Solutions filed an SEC 8-K on 2026-08-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Thermo Fisher, Cytiva, Azenta, or other life-science suppliers win validation in major cell-and-gene-therapy manufacturing processes as preferred alternatives to BioLife products.
- Competitors demonstrate equivalent preservation outcomes with simpler bridging data, lowering the perceived risk of switching.
- FY2025 GAAP annual operating income fell to a loss of $16.602 million despite higher revenue, suggesting operating costs absorbed the gross profit gains.
- A renewed biotech funding downturn delays orders from clinical-stage cell-and-gene-therapy customers and stretches receivables.
BLFS news
Loading headlines…
Financial statements
BLFS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.